GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
| Business Activity | PASS |
| Debt Ratio (0.28%) | PASS |
| Cash Ratio (0.01%) | PASS |
| Receivables Ratio (0.22%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-29 | 1.03 | Pending | -- |
| 2026-04-29 | 1.05 | 0.99 | -5.7% |
| 2026-02-04 | 1.40 | 1.44 | +3.0% |
| 2025-10-29 | 1.00 | 0.98 | -2.2% |
| 2025-07-30 | 0.92 | 1.06 | +15.4% |
| 2025-04-30 | 0.91 | 1.01 | +10.6% |
| 2025-02-13 | 1.26 | 1.45 | +14.8% |
| 2024-10-30 | 1.05 | 1.14 | +8.3% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5.1B | $389.0M | $755.0M | $2.0B | $515.0M | 0.85 |
| 2025-12-31 | $5.7B | $589.0M | $1.1B | $2.3B | $827.0M | 1.29 |
| 2025-09-30 | $5.1B | $446.0M | $902.0M | $2.0B | $653.0M | 0.98 |
| 2025-06-30 | $5.0B | $486.0M | $874.0M | $2.0B | $654.0M | 1.06 |
| 2025-03-31 | $4.8B | $564.0M | $939.0M | $2.0B | $628.0M | 1.23 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-12 | HOCHMAN RODNEY F | Director | 1,618 | $100.4K |
| 2026-05-08 | YANG WATKIN PHOEBE L | Director | 1,000 | $63.0K |
| 2026-05-07 | YANG WATKIN PHOEBE L | Director | 3,586 | -- |
| 2026-05-07 | HOCHMAN RODNEY F | Director | 6,275 | -- |
| 2026-05-07 | MADDEN ANNE T | Director | 5,868 | -- |
| 2026-05-07 | CULP HENRY LAWRENCE JR. | Director | 7,743 | -- |
| 2026-05-07 | LESJAK CATHERINE ANNE | Director | 3,586 | -- |
| 2026-05-06 | CULP HENRY LAWRENCE JR. | Director | 80,805 | $5.0M |
| 2026-05-06 | STROMBERG WILLIAM J | Director | 1,000 | $61.7K |
| 2026-05-01 | SACCARO JAMES | Chief Financial Officer | 3,310 | $200.6K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 36.0M | $2.3B | 0.1% |
| Dodge & Cox Inc. | 31.3M | $2.0B | 0.1% |
| Vanguard Capital Management LLC | 28.9M | $1.9B | 0.1% |
| Capital Research Global Investors | 21.1M | $1.4B | 0.0% |
| State Street Corporation | 20.5M | $1.3B | 0.0% |
| Vanguard Portfolio Management LLC | 19.2M | $1.2B | 0.0% |
| Harris Associates L.P. | 15.6M | $1.0B | 0.0% |
| Geode Capital Management, LLC | 12.4M | $796.4M | 0.0% |
| Barrow, Hanley Mewhinney & Strauss, LLC | 11.9M | $763.3M | 0.0% |
| Hotchkis & Wiley Capital Management, LLC | 10.0M | $640.2M | 0.0% |
$37.8B
2.74
0.868
19
$21.0B
$10.6B
-30.9%
0.2%
1.89
2.70
0.0%
54,000
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-29 | $1.03 | Pending | — |
| 2026-04-29 | $1.05 | $0.99 | -5.7% |
| 2026-02-04 | $1.40 | $1.44 | +3.0% |
| 2025-10-29 | $1.00 | $0.98 | -2.2% |
| 2025-07-30 | $0.92 | $1.06 | +15.4% |
| 2025-04-30 | $0.91 | $1.01 | +10.6% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($79.63, 19 analysts) | |||
| 10 | $612.85 | +$183.50 (30%) | 2.0R |
| 50 | $3,064.25 | +$917.50 (30%) | 2.0R |
| 100 | $6,128.50 | +$1,835.00 (30%) | 2.0R |
| To Fair Value ($64.57) | |||
| 10 | $612.85 | +$32.80 (5%) | 0.4R |
| 50 | $3,064.25 | +$164.00 (5%) | 0.4R |
| 100 | $6,128.50 | +$328.00 (5%) | 0.4R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| CRBN | 0.614 |
| AMANX | 0.609 |
| XLB | 0.601 |
| VTI | 0.598 |
| IVV | 0.596 |
| Ticker | Correlation |
|---|---|
| BAES.L | -0.218 |
| BBLNF | -0.165 |
| ITHMR.AE | -0.165 |
| COL.AX | -0.159 |
| 2269.T | -0.156 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.